

Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000 • 510-236-8951(Fax)

**SANGAMO BIOSCIENCES TO RELEASE FOURTH-QUARTER AND YEAR-END 2000
FINANCIAL RESULTS ON FEBRUARY 1, 2001**

Richmond, California – January 25, 2001 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth-quarter and year-end financial results on Thursday, February 1, 2001 after the market closes. The earnings release will be followed by a conference call at 2:00 p.m. PST, which will be open to the public. During the conference call, the company will review these results and provide guidance for 2001.

The conference call dial-in numbers are 800-730-7991 for domestic callers and 706-634-7552 for international callers. For those unable to listen in at the designated time, a conference call replay will be available for 1 week following the conference call, from approximately 4:00 p.m. PST on February 1, 2001 to 4:00 p.m. PST on February 8, 2001. The conference call replay numbers for domestic and international callers are 800-642-1687 and 706-645-9291 respectively. The conference ID number for the replay is 33601.

About Sangamo

Sangamo is focused on the research and development of novel transcription factors for the regulation of gene expression. Sangamo's Universal Gene Recognition™ technology enables the engineering of transcription factors known as zinc finger DNA binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors that can control gene expression and, consequently, cell function. The company intends to establish Universal Gene Recognition as a widely used technology for commercial applications in pharmaceutical discovery, human therapeutics, clinical diagnostics, agriculture and industrial biotechnology. Over twenty leading pharmaceutical and biotechnology companies have utilized ZFPs. In addition, Sangamo has a strategic alliance with Edwards Lifesciences Corporation to develop novel therapeutics for the treatment of cardiovascular disease. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbors created by those sections. Actual results may differ materially from these forward-looking statements. See the company's SEC filings, and in particular, the risk factors described in the company's Prospectus on Form S-1 and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release. Further, Sangamo assumes no obligation to update any guidance given on its upcoming conference call.

Contact: Julie Wood
Sr. Director, Corporate Communications
510-970-6000, x256

###